newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported